Compare RBB & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RBB | LXEO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.0M | 396.5M |
| IPO Year | 2017 | 2023 |
| Metric | RBB | LXEO |
|---|---|---|
| Price | $26.56 | $4.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $22.00 | $18.44 |
| AVG Volume (30 Days) | 203.3K | ★ 972.8K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.68% | N/A |
| EPS Growth | 24.49 | ★ 39.81 |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $5,167,000.00 | $654,000.00 |
| Revenue This Year | $20.50 | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $39.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.74 | $4.03 |
| 52 Week High | $28.24 | $10.99 |
| Indicator | RBB | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 50.36 | 45.79 |
| Support Level | $20.11 | $4.30 |
| Resistance Level | $28.22 | $5.36 |
| Average True Range (ATR) | 0.80 | 0.35 |
| MACD | -0.20 | -0.00 |
| Stochastic Oscillator | 34.06 | 18.37 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.